Latest Neurodiagnostics News

Page 1 of 2
EMVision Medical Devices has secured a new $3 million non-dilutive CRC-P grant to adapt and clinically test its First Responder scanner for traumatic brain injury. The project adds a second potential indication to the device, but remains dependent on funding agreements, clinical evidence and regulatory clearance.
Victor Sage
Victor Sage
20 Nov 2026
EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.
Ada Torres
Ada Torres
27 May 2026
EMVision Medical Devices has ramped up recruitment in its pivotal FDA trial across eight hospitals and is nearing results from multiple pre-hospital studies, all while bolstering its cash position with a $3.8 million R&D tax refund and $6.6 million in grant funding.
Ada Torres
Ada Torres
13 Apr 2026
EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.
Ada Torres
Ada Torres
16 Mar 2026
EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.
Ada Torres
Ada Torres
23 Feb 2026
TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.
Ada Torres
Ada Torres
5 Nov 2025
EMVision Medical Devices has successfully closed an oversubscribed Share Purchase Plan, raising $2 million and bringing total recent capital to $14 million. This funding positions the company to advance pivotal clinical trials and regulatory milestones for its innovative neurodiagnostic devices.
Ada Torres
Ada Torres
31 Oct 2025
EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.
Ada Torres
Ada Torres
28 Oct 2025
EMVision Medical Devices has closed its $2 million Share Purchase Plan ahead of schedule due to strong investor demand, signaling robust market interest in its neurodiagnostic technology.
Ada Torres
Ada Torres
21 Oct 2025
EMVision Medical Devices’ latest Share Purchase Plan has attracted applications exceeding its initial $1 million target, with limited oversubscription capacity remaining ahead of the October 23 closing date.
Ada Torres
Ada Torres
16 Oct 2025
EMVision Medical Devices has initiated a unique pre-hospital study in Melbourne to test its First Responder Brain Scanner within one of the world’s few Mobile Stroke Units, aiming to enhance stroke diagnosis and accelerate commercialisation.
Ada Torres
Ada Torres
24 Sept 2025
EMVision Medical Devices has raised $12 million through a placement backed by institutional investors, including strategic partner Keysight Technologies, and launched a Share Purchase Plan to raise up to $2 million from existing shareholders. The capital will support key clinical and regulatory milestones for its neurodiagnostic devices over the next two years.
Ada Torres
Ada Torres
17 Sept 2025

Browse the archive

Full archive